We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Zambia is experiencing a shortage of pediatric HIV testing kits and antiretroviral (ARV) drugs for children, the UN Integrated Regional Information Networks (IRIN) reports.
U.S. drugmaker Eli Lilly announced it is stopping construction of an insulin manufacturing plant in Virginia because demand is not as high as the company thought when it planned the facility in 2003.
French drugmaker sanofi-aventis announced that the German Ministry of Health has ratified the recommendation of the German Federal Joint Committee to classify the company's weight-loss drug Acomplia (rimonabant) as a non-reimbursable, or lifestyle, drug.
Peregrine Pharmaceuticals, a company that develops targeted therapeutics for the treatment of cancer and hepatitis C virus infection, announced it has established a wholly foreign-owned enterprise in China.
The Treatment Action Group (TAG) announced it has been awarded a four-year $4.7 million grant from the Bill & Melinda Gates Foundation to expand its project to combat the HIV and tuberculosis (TB) epidemics.
A bipartisan group of U.S. House of Representative members is continuing to push for passage of a bill allowing the government to negotiate drug prices for Medicare Part D, even while the government agency in charge of the program said the bill will not save money.
Swedish drugmaker BioInvent announced it has entered into a strategic collaboration with Genentech to develop and commercialize BioInvent's proprietary antibody candidate, BI-204, for the potential treatment of multiple cardiovascular conditions.
Nicholas Piramal India and Eli Lilly have signed a drug-development agreement to develop and, in certain regions, commercialize a select group of Lilly's preclinical drug candidates that span multiple therapeutic areas.